Obexelimab is a monoclonal antibody designed to bind both CD19 and FcγRIIb receptors and inhibit the activity of B-cells linked to autoimmune diseases.

While the company’s bispecific medication obexelimab met its objectives in a trial in IgG4-related disease, it didn’t appear ...

Obexelimab met the primary endpoint demonstrating a clinically meaningful and highly statistically significant 56% reduction in risk of IgG4-RD ...

—Investigators in Argentina recently examined a small subset of patients with immunoglobulin G4-related disease (IgG4-RD) and pulmonary findings to learn more about this immune-mediated, multiorgan ...

Sanofi ((SNYNF)) announced an update on their ongoing clinical study. Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help ...

Please provide your email address to receive an email when new articles are posted on . B-cell depletion with inebilizumab reduced flare risk for pancreatic and/or biliary IgG4-related disease. It ...

Inebilizumab-cdon is the first FDA-approved treatment for IgG4-related disease, targeting CD19+ B cells to reduce inflammation and fibrosis. The MITIGATE trial showed inebilizumab significantly ...

Inebilizumab significantly reduced the risk of treated and AC-determined IgG4-RD flare by 87% compared with placebo. The Food and Drug Administration (FDA) has approved Uplizna ® (inebilizumab-cdon) ...

The US Food and Drug Administration (FDA) has approved the B-cell depleting agent inebilizumab-cdon (Uplizna, Amgen) for the treatment of immunoglobulin G4-related disease (IgG4-RD). This is the first ...

IgG4-related disease (IgG4-RD) is a chronic autoimmune condition that may affect multiple organs in your body, causing tissue swelling and organ damage. Because no single test can definitively ...

Amgen Inc ($AMGN) announced an update on their ongoing clinical study. Amgen’s latest clinical move targets a niche but ...